CT features of HER2-mutant lung adenocarcinomas
Sign Up to like & getrecommendations! Published in 2018 at "Clinical imaging"
DOI: 10.1016/j.clinimag.2018.05.028
Abstract: Objectives: To describe the radiological phenotype of HER2-mutant lung cancers on CT at presentation. Methods: Eligible patients with lung adenocarcinomas with HER2 mutations were stage-matched with two control groups (EGFR- and KRAS-mutant groups). Evaluated CT… read more here.
Keywords: her2 mutations; presence pleural; mutant lung; lung adenocarcinomas ... See more keywords
In vitro validation study of HER2 and HER4 mutations identified in an ad hoc secondary analysis of the LUX-Lung 8 randomized clinical trial.
Sign Up to like & getrecommendations! Published in 2021 at "Lung cancer"
DOI: 10.1016/j.lungcan.2021.10.014
Abstract: OBJECTIVES The LUX-Lung 8 randomized trial (LL8) demonstrated a prolonged progression-free survival (PFS) in patients with metastatic squamous cell carcinoma (SCC) of the lung after treatment with afatinib compared with erlotinib. A secondary analysis of… read more here.
Keywords: her2 mutations; her4 mutations; lung; her2 her4 ... See more keywords
Abstract 4952: Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to ER-directed therapies
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-4952
Abstract: Despite the reduction in cancer recurrence and mortality provided by therapies that target the estrogen receptor (ER), resistant ER+ breast cancer remains the most common cause of breast cancer death. Beyond mutations in ER in… read more here.
Keywords: her2 mutations; resistance directed; breast cancer; resistance ... See more keywords
Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial
Sign Up to like & getrecommendations! Published in 2022 at "BMC Medicine"
DOI: 10.1186/s12916-022-02245-z
Abstract: Background There is currently a lack of effective treatments for non-small cell lung cancer (NSCLC) patients harboring HER2 mutations. We examined the efficacy and safety of, and potential resistance mechanism to, pyrotinib, a pan-HER inhibitor,… read more here.
Keywords: safety; her2 mutations; efficacy safety; trial ... See more keywords
Associations of HER2 Mutation With Immune-Related Features and Immunotherapy Outcomes in Solid Tumors
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.799988
Abstract: Background HER2 is one of the most extensively studied oncogenes in solid tumors. However, the association between tumor microenvironment (TME) and HER2 mutation remains elusive, and there are no specific therapies for HER2-mutated tumors. Immune… read more here.
Keywords: immunotherapy outcomes; her2 mutations; solid tumors; mutation ... See more keywords